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Abstract Several lines of evidence suggest a role for the gut
microbiome in type 1 diabetes. Treating diabetes-prone ro-
dents with probiotics or antibiotics prevents the development
of the disorder. Diabetes-prone rodents also have a distinctly
different gut microbiome compared with healthy rodents.
Recent studies in children with a high genetic risk for type 1
diabetes demonstrate significant differences in the gut
microbiome between children who develop autoimmunity
for the disease and those who remain healthy. However, the
differences in microbiome composition between autoimmune
and healthy children are not consistent across all studies be-
cause of the strong environmental influences on microbiome
composition, particularly diet and geography. Controlling
confounding factors of microbiome composition uncovers
bacterial associations with disease. For example, in a human
cohort from a single Finnish city where geography is con-
fined, a strong association between one dominant bacterial
species,Bacteroides dorei, and type 1 diabetes was discovered
(Davis-Richardson et al. Front Microbiol 2014;5:678).
Beyond this, recent DNA methylation analyses suggest that
a thorough epigenetic analysis of the gut microbiome may be
warranted. These studies suggest a testable model whereby a
diet high in fat and gluten and low in resistant starch may be
the primary driver of gut dysbiosis. This dysbiosis may cause
a lack of butyrate production by gut bacteria, which, in turn,
leads to the development of a permeable gut followed by
autoimmunity. The bacterial community responsible for these
changes in butyrate production may vary around the world,
but bacteria of the genus Bacteroides are thought to play a key
role.
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Introduction
The incidence of type 1 diabetes in many developed countries
has been increasing at rates faster than can be explained by the
known genetic propensity towards the disease [1]. The envi-
ronmental triggers of this disease have not yet been identified,
despite the many efforts to associate diet, vitamin D, viruses
and other factors with disease [1]. A leaky gut has been cor-
related with type 1 diabetes [2], and an aberrant gut
microbiome was proposed as the factor that results in a leaky
gut followed by altered immune responses leading to disease
[3]. This review describes a model for the role of the gut
microbiome in type 1 diabetes based on the latest results.
Animal models
Past work with non-obese diabetic (NOD) mice and
BioBreeding diabetes-prone (BB-DP) rats provided the first
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evidence that bacteria may play an important role in the onset
of type 1 diabetes. BB-DP rats fed sulfamethoxazole, trimeth-
oprim and colistin sulphate demonstrate a significantly de-
creased incidence of diabetes compared with controls [4]. A
similar increase in disease-free animals vs controls was ob-
served in NOD mice after administration of doxycycline or
vancomycin [5, 6]. Bacteroideswere higher in stools from the
BB-DP rat while Lactobacillus was higher in the diabetes-
resistant rat (BB-DR) [7]. Strains of Lactobacillus johnsonii
and Lactobacillus reuteri isolated from BB-DP rats prevented
and promoted diabetes in BB-DP rats, respectively [8]. The
L. johnsonii strain induces a T helper 17 cell bias in the mes-
enteric lymph nodes of C57BL/6 mice while the L. reuteri
strain does not [9].
Although the incidence of insulitis is not significantly dif-
ferent between germ-free and specific-pathogen-free (SPF)
NOD mice, germ-free mice develop insulitis earlier than
SPF mice [10, 11]. The presence of segmented filamen-
tous bacteria (SFB) in female NOD mice is correlated
with decreased insulitis incidence and with the percent-
age of IL-17-expressing lymphocytes [12].
Diet is known to significantly affect diabetes incidence in
NOD mice. For example, a high-cereal diet increases diabetes
incidence in NODmice, while a high-protein diet reduces risk
[13]. Recent studies observed that acidic drinking water also
increases diabetes incidence in NOD mice, and this is
prevented by inoculating mice with SFB [14].
Humans
The results of the murine experiments encouraged efforts to
determine whether associations between gut bacteria and type
1 diabetes could be discovered in humans. Rodent model in-
vestigations suggested that healthy children may have high
populations of probiotic-like bacteria such as Lactobacillus,
while the gut microbiome of unhealthy children may be dom-
inated by Bacteroides. Perhaps antibiotic or probiotic use ear-
ly in life could prevent type 1 diabetes, but this requires more
study. Analysis of a Finnish dataset revealed no connection
between antibiotic use and autoimmunity for type 1 diabetes
[15], but larger cohorts may be needed to observe an antibiotic
influence on this disease. Early on, a simple picture was ex-
pected to emerge by simply studying the stool content of a few
human cohorts with individuals at high genetic risk of type 1
diabetes.
At first, with very small human cohorts with only four
healthy children and four children with type 1 diabetes auto-
antibodies from the Diabetes Prediction and Prevention
(DIPP) study in Finland, the human situation did appear to
be very similar to the murine one [16, 17]. These studies
showed highly significant taxonomic and functional differ-
ences between cases and controls prior to autoimmunity for
type 1 diabetes. Levels of Bacteroides were higher in children
with autoimmunity, and levels of seemingly protective unclas-
sified Firmicutes were higher in healthy children. These re-
sults match the findings of the murine experiments except for
the fact that the human samples had negligible amounts of
Lactobacillus.
Contrasting results were obtained from an investigation of
298 stool samples collected during the first 3 years of age from
22 case and 22 control children enrolled in the German
BABYDIET study [18]. Unlike the small Finnish cohort, no
significant differences between taxa were observed between
cases and controls after correction for false discovery rate.
Instead, network analysis showed that bacterial communities
in cases were far less strongly correlated with each other at
<6 months of age and again at about 2 years of age than in
controls. However, the results from the Finnish and German
cohorts were similar in that the autoimmune bacterial commu-
nities were less stable than the healthy communities. The
cause for this instability in autoimmune samples remains
unknown.
A still larger set of 947 stool samples collected during the
DIPP study from 29 cases and 47 controls during the first
4 years of life was examined [15]. All of the children enrolled
in the DIPP study are genetically at high risk for type 1 dia-
betes. Analysis of these samples revealed a very striking re-
sult: approximately 8 months prior to the average time of
appearance of the first autoantibody in cases, a large increase
in one bacterial species, Bacteroides dorei, was observed. In
addition, B. dorei was by far the most abundant species in
autoimmune prone children, with over 20% of the population
represented by this one species—a rate that was more than
double the relative abundance of this species in healthy chil-
dren. This difference was highly statistically significant even
after correcting for false discovery rate and was found to occur
at about the same time as the introduction of solid food. A few
other minor taxonomic differences were also observed, but
nothing as striking as the B. dorei result.
So why was the B. dorei result seen in the large Finnish
DIPP cohort but not in the German BABYDIET study? At
first glance, it may appear that since the B. dorei result in
Finland was not reproduced in Germany, it must then be an
anomaly. However, there is one very important difference be-
tween the designs of these two cohorts that may explain this
difference. The samples used in the DIPP study were all from
children born in the same hospital, Turku University Hospital
[15]. All of the children lived within 80 km of each other.
Thus, many of the known confounders of the microbiome
community were controlled; that is, climate, diet, culture, wa-
ter supply, pollution levels, air quality and medical practices
were all very similar for these children.
In contrast, the children in the BABYDIET cohort were
from all over Germany, allowing enough variability in the
microbiome confounders to affect microbiome composition.
In addition, all of the children in the BABYDIET study had
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first-degree relatives with type 1 diabetes, while in DIPP the
children were chosen for the study based on their high-risk
HLA genotype at birth. These confounders add to the noise of
the data and may explain why no significant taxonomic dif-
ferences were observed between cases and controls. These
confounders may have been sufficient to mask any taxonomic
differences that might otherwise have been detected in the
BABYDIET study but too weak to mask the network differ-
ences seen in this cohort [18].
Hence, a working hypothesis is that geography plays a very
large role in whether it is possible to observe significant case–
control differences in any cohort designed to examine associ-
ations between the microbiome and disease. From this per-
spective, the microbiome results from the BABYDIET and
DIPP cohorts do not contradict each other but rather help us
understand how best to design cohorts for future disease-
related microbiome studies.
Two other recent studies from Europe and Mexico showed
taxonomic differences in the gut microbiome between individ-
uals with type 1 diabetes and individuals without the disease
[19, 20]. In both studies, levels of Bacteroides were signifi-
cantly higher in those children with type 1 diabetes compared
with healthy children. These studies were intended to show
the effect of the disease itself as opposed to identifying a
trigger for autoimmunity as in the previous studies. The
Mexican study was restricted to Sonora state, which borders
Arizona, and was limited to 29 children, including eight con-
trols. Based on the findings of these studies and the pre-
autoimmunity cohorts described above, Bacteroides appears
to be a major contributor to microbiome dysbiosis both prior
to the development of autoimmunity and after disease
diagnosis.
There is evidence that the human genome has some
control over the taxonomic composition of bacteria in
the gut. However, it is not known whether a genetic
propensity to type 1 diabetes, as manifested by HLA
genotype, affects bacterial gut composition [21]. The
studies conducted to date on the relationship between
type 1 diabetes autoimmunity and the microbiome have
not seen an HLA genotype effect on the microbiome,
but these studies did not have enough participants to
observe such an effect [15, 18].
The hygiene hypothesis suggests that a lack of expo-
sure to microbes early in life under hygiene conditions
in the developed world contributes to a weakened im-
mune system incapable of warding off the effects of
detrimental bacteria in the gut [22]. Efforts are under-
way to examine this issue carefully between Finland
and neighbouring Estonia and Russian Karelia [22].
Testing this hypothesis will be difficult in any study
protocol. Our view that separating signal from noise is
best done by careful cohort design intended to reduce
the confounders of the microbiome.
Approaches to reduce these confounders in cohort
design
Our recent results suggest that striking case–control differ-
ences can be observed when the geographic distribution of a
high-risk cohort is limited to one city and its immediate sur-
roundings. Another issue is whether type 1 diabetes risk is
higher in urban or rural areas [23]. Differences in large gut
microbiome taxa and alpha diversity differences were recently
observed across six clinical sites in children at high genetic
risk for type 1 diabetes [24]. Higher socioeconomic status is
typically associated with type 1 diabetes and other autoim-
mune diseases [25]. To date there are no reports in the litera-
ture on socioeconomic status and gut microbiome composi-
tion, but socioeconomic status has been shown to be associat-
ed with the oral microbiome [26]. However, given that geog-
raphy and diet are well known to affect gut microbiome com-
position and that socioeconomic status affects diet and place
of residence, cohort design should take these factors into ac-
count or in some way control for them. To date, no clear
associations between type 1 diabetes and diet have beenmade,
but this is being carefully examined by The Environmental
Determinants of Diabetes in the Young (TEDDY) study group
[27].
An ideal cohort design might be one that includes samples
from a set of cities similar to Turku where the cohort includes
children all born in the same hospital and all living in the
surrounding area. The variability of other environmental fac-
tors, such as climate, drinking water, health practices and air
quality, are similar across a single city. Having a set of such
cities each with children at high risk might allow us to identify
bacteria or bacterial functions that are associated with autoim-
munity for type 1 diabetes across a broad geographic scale.
Sampling from families may be a means of reducing the
noise in the microbiome data. That is, rather than collecting
samples from healthy controls matched for genetic risk, con-
trol samples could be obtained from healthy siblings. But age
matching is important, so noise could be further controlled by
enrolling identical and non-identical twins for the study of
those at high genetic risk for the disease at birth. This would
be a difficult undertaking in a small city such as Turku but
might work well in a much larger city in the same country,
such as Helsinki.
Another way of reducing noise would be to determine the
changes that can occur in the gut microbiome communities in
stools in response to long-term exposure to room temperature
and air. Approaches must be developed that make it easier for
families to collect stools in a manner that allows for rapid
freezing. Microbial communities in stools do change signifi-
cantly after 24 h of exposure to air, and these changes include
a sharp decline in the relative abundance of Bacteroides
strains [28], which can survive air but do not divide under
aerobic conditions. To date, none of the studies to investigate
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the microbiome of children at high genetic risk for type 1
diabetes has been designed with the microbiome in mind. In
addition to the aforementioned improvements in study design
and larger cohorts with limited confounding, advancements in
big data analysis methods should also help to facilitate within-
and between-study analyses.
Does the B. dorei genome suggest functions
associated with the development of autoimmunity
for type 1 diabetes?
As described above, a recent study showed a strong associa-
tion between high levels of B. dorei in the gut several months
prior to the appearance of the first type 1 diabetes autoanti-
body [15]. A first step towards determining whether B. dorei
causes type 1 diabetes autoimmunity would be to culture it
from the Turku DIPP samples, then inoculate NOD mice with
this organism and determine whether this strain(s) reduces the
survival rates of the mice. Although this is a high-risk strategy
and not without significant intellectual challenges, it would be
worthwhile to conduct such an experiment because even
though B. dorei may not be involved in type 1 diabetes onset
in other populations, a certain set of functions expressed by
B. dorei may have wide applicability to autoimmune disease
around the globe.
As more bacterial metagenomes are obtained from stool
samples of high-risk children, quantifying the relative abun-
dance of homologues or paralogues of B. dorei genes will be
an easy task. Additional Bacteroides species may be associat-
ed with type 1 diabetes autoimmunity in other cohorts, which
will allow us to build a database of genes in common with all
Bacteroides associated with diseases vs those genes in
Bacteroides species not associated with disease. A similar
approach can be used on bacterial species or strains thought
to be protective against the disease. Bacterial functions asso-
ciated with disease have been listed for a very small cohort
from the DIPP study [16]. Further studies are warranted on an
increased number of individuals and more samples across ad-
ditional time points.
Is diet the source of high levels of Bacteroides
associated with type 1 diabetes autoimmunity?
As Bacteroides have been associated with type 1 diabetes
autoantibodies, the next obvious question pertains to the
source of these bacteria. That is, if a single species or set of
closely related species is associated with type 1 diabetes, the
need to hunt for more bacterial associations with type 1 dia-
betes declines and the problem becomes one of searching for
those environmental factors that increase the abundance of
these Bacteroides species in the gut. In the stool samples of
autoimmune Turku children, levels of B. dorei peak at about
7 months of age, about 1 month prior to the Finnish national
standard for the timeframe of solid food introduction [15]. If
the early introduction of solid food is related to raised
Bacteroides levels, which foods are known to increase
Bacteroides abundance in the gut?
High-fat and high-gluten diets encourage colonisation of
the gut by Bacteroides. Bacteroides populations in the human
gut have been strongly correlated with a diet high in protein,
animal fat, cholesterol and other fats [29].Bacteroides are well
known as the primary proteolytic bacteria in the gut [30]. Not
surprisingly, vegans and vegetarians have low levels of
Bacteroides in their stools [31]. To date, connections between
a vegetarian diet and the progression towards type 1 diabetes
have not been studied.
Examination of the gut microbiome in coeliac disease sug-
gests that gluten may play a role in Bacteroides abundance.
The prevalence of B. dorei was 67% higher in children with
active coeliac disease compared with the same children on a
gluten-free diet for two years [32]. Similarly, formula-fed chil-
dren at high risk for coeliac disease were approximately six-
times more likely to possess B. dorei in stool than low-risk
controls [33]. These results encourage further work to deter-
mine whether gluten increases population growth of B. dorei
in children at high risk for autoimmunity. Resistant starch may
also play a significant role in preventing type 1 diabetes as it
has been reported to increase faecal butyrate levels [34].
Association between gut integrity and type 1 diabetes
in humans
The onset of type 1 diabetes might involve an aberrant intes-
tinal microbiome creating the conditions for gut leakiness
followed by mucosal immune responses that lead to an attack
of insulin-producing islet cells [3]. Consistent with this notion,
type 1 diabetic individuals have been shown to have a leakier
gut than controls [35–37], and it has been reported that this
leakiness is not caused by type 1 diabetes, rather, type 1 dia-
betes is preceded by a leaky gut [2]. In the NODmousemodel,
a leaky gut can lead to the activation of diabetogenic CD8+
cells which, in turn, lead to the development of insulitis [38].
Mechanisms for a connection between the leaky gut and type
1 diabetes have been reviewed previously [39, 40].
A role for short-chain fatty acids and gut integrity
Butyrate is one of the short-chain fatty acids (SCFAs) pro-
duced by bacterial fermentation in the gut. The ratio of
butyrate:acetate:proprionate in the gut varies widely, but these
three SCFAs make up the majority of the SCFA content in this
organ. The concentration of SCFAs in the gut can be as high as
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140 mmol/l and these SCFAs can provide up to 10% of the
daily human caloric needs [41]. Butyrate reduces trans-
membrane transport of Escherichia coli across confluent
monolayers of colon-derived cell lines [42]. In addition, in-
flammation may reduce butyrate transport through the down-
regulation of a butyrate transporter [43].
Butyrate is also known to play two important roles in
maintaining the integrity of the epithelial layer. First,
butyrate induces the expression of mucin-producing
genes in the epithelial layer [44]. Mucin is a host gly-
coprotein that protects the epithelial layer from attack
by bacteria or bacterial metabolites. Second, butyrate
restores and maintains tight junction assembly in epithe-
lial layers [45, 46]. These tight junctions are formed
between epithelial cells and serve as gatekeepers for
metabolite transport across the epithelium. Other
SCFAs do not induce tight junction formation or mucin
synthesis.
Healthy children have a higher proportion of butyrate-
producing gut bacteria in their microbiomes compared with
children expressing at least one beta islet cell autoantibody
[16, 47]. Based on this, the ratio of butyrate-producing to other
SCFA-producing bacteria in the gut was proposed to be a key
regulator in determining the gut health of a child at high risk
for type 1 diabetes [16]. However, there is no evidence to date
linking butyrate levels in the gut to the progression of diabetes
in either animals or humans.
Can gut bacteria regulate the epigenome
of the human epithelial cell?
Butyrate has roles other than maintenance of the integrity of
the gut epithelial layer. In particular, there is increasing evi-
dence that butyrate has epigenetic effects that may be very
important in type 1 diabetes, as unknown environmental trig-
gers must be playing a role in the rapid increase in the inci-
dence of this disease [48].
Butyrate induces the methylation of promoter regions,
which causes both up- and downregulation in different sets
of human genes [49]. Histone acetylation also appears to be
regulated by butyrate production. Butyrate reduces
lipopolysaccharide-induced inflammation in the intestine
throughmodulation of antioxidant defence systems [50], nitric
oxide production, and expression of inflammatory cytokines
[51]. Many of these effects appear to be modulated by the
inhibition of histone deacetylases in macrophages [51].
Also, histone acetylation in the promoter of the Foxp3 locus
Beginning with the
introduction of solid food,
consume a diet predominant in:
High fat, high gluten,
low resistant starch


















Fig. 1 Model for the development of autoimmunity for type 1 diabetes based on a diet-induced disproportionate high number of Bacteroides in the gut,
leading to a leaky gut and autoimmunity for the disease
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induces the differentiation of regulatory T cells in mice [52].
Several epigenetic changes in host epithelial cells may be
caused by increased butyrate production from probiotic strains
[53].
Is there a role for the methylome of the gut
microbiome in the development of type 1 diabetes
autoimmunity?
The genomes of two of the B. dorei strains from the DIPP
Turku cohort have been sequenced to completion and, physi-
ologically, appear to be typical Bacteroides in that they
metabolise a broad spectrum of compounds and have many
antibiotic-resistance genes [54]. One of these genomes was
derived from a child who later developed type 1 diabetes-
associated autoantibodies (case) while the other genome was
from a high-risk healthy child (control). The case genome in-
cludes a bacteriophage with a DNA adenine methyltransferase
gene that appears to be responsible for the methylation of all
but three of the 20,554 GATCmotifs in the genome [54]. Such
phage-borne DNAmethyltransferases have been found in sev-
eral bacteria [55]. None of the nearly 19,000 GATC motifs in
the control genome were methylated, presumably because it
lacked this phage and its orphan DNAmethyltransferase gene.
This work was the first report of DNAmethylation differences
within a bacterial species in the microbiome [54].
Although these methylation results from two B. dorei ge-
nomes cannot be associated with disease, they suggest that a
wider examination of methylation patterns in more samples is
warranted. DNA methylation patterns are known to affect
gene expression in bacteria [56]. They control epigenetic re-
sponses that are often regulated by environmental exposure.
Indeed, a few methylation sites in the human genome have
been associated with type 1 diabetes pathogenesis [57, 58]. It
is therefore conceivable that methylation differences in the
genomes of bacteria associated with type 1 diabetes may play
a role in disease.
Conclusions
The analyses described above suggest a revised model for the
role of the microbiome in type 1 diabetes, one that is based on
a previous model [16] but takes into account the role of diet
(Fig. 1). In this revised model, type 1 diabetes autoimmunity
occurs when a high-fat, high-gluten diet, perhaps one with a
low level of resistant starch, increases Bacteroides colonisa-
tion in the gut. These bacteria ferment glucose to SCFAs other
than butyrate. The lack of butyrate production reduces the
likelihood of an intact gut epithelial layer. The resulting per-
meability causes bacterial antigen exposure that induces im-
mune responses leading to type 1 diabetes autoimmunity.
Recent results suggest that the many confounders of gut
microbiome composition need to be considered in cohort de-
sign for the optimal discovery of associations between the gut
microbiome and disease. A cohort carefully designed to con-
trol for geography and diet as much as possible can eliminate
much of the noise that is often associated with microbiome
data. Future work will require experiments or observational
studies that directly test each point in the model (Fig. 1).
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